<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291641</url>
  </required_header>
  <id_info>
    <org_study_id>IMT-01</org_study_id>
    <nct_id>NCT01291641</nct_id>
  </id_info>
  <brief_title>Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy</brief_title>
  <acronym>IMPACTonIMT</acronym>
  <official_title>Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the additional effect of probucol or concomitant
      administration of cilostazol and probucol on mean carotid artery intima-media thickness (mean
      IMT) at year 1, 2, and 3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperlipidemic patients who are currently receiving HMGCoA reductase inhibitors(Statins) will
      be randomized Group A(Control), Group B(Probucol only added group) or Group C(Probucol and
      cilostazol added group) . Randomization will be done by the minimization method, controlling
      for the following factors: Country(Korea vs China) and max IMT (≥2.0mm vs.&lt;2.0mm).

      Group A : HMGCoA reductase inhibitor continued

      Group B : HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID

      Group C : HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID +Cilostazol 100 mg
      PO, BID
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of Carotid artery IMT (mean IMT) between screening and treatment completion(3 years after) or discontinuation</measure>
    <time_frame>Baseline(screening), 3years</time_frame>
    <description>For primary endpoint of Carotid artery IMT, t-test will be conducted for the mean IMT and variation by treatment arm(Group A vs B, Group A vs C). The 2-sided significance level is 5%. Morever, Mantel - Haenszel method can be accepted considering stratification factor or Sub-analysis can be done by each stratum in case of categorical variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from enrollment date to the onset of composite cerebrovascular events</measure>
    <time_frame>enrollment date, onset date(during study period, 3years)</time_frame>
    <description>Cardiovascular death
Myocardial infarction
Cerebral infarction
Unstable angina and cardiac failure, required hospitalization
Coronary revascularization, required hospitalization
PCI and coronary artery bypass grafting [CABG]
Kaplan-Meier method will be conducted for the time from enrollment date to the onset of composite cerebrovascular and cardiovascular events by treatment arm(Group A vs B, Group A vs C). Overall survival curves and progression-free survival curves are estimated per treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of composite cerebrovascular and cardiovascular events(including intervention)</measure>
    <time_frame>enrollment date, onset date(during study period, 3years)</time_frame>
    <description>Cardiovascular death
Myocardial infarction
Cerebral infarction
Unstable angina and cardiac failure, required hospitalization
Coronary revascularization, required hospitalization
PCI and coronary artery bypass grafting [CABG]
For the number of composite cerebrovascular and cardiovascular events (including intervention) t-test will be done by treatment arm(Group A vs B, Group A vs C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Biomarkers(1)</measure>
    <time_frame>enrollment date ,onset date(during study period, 3years)</time_frame>
    <description>Metabolic index: Lipid profile (TC, LDL-C, HDL-C, TG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Biomarkers(2)</measure>
    <time_frame>enrollment date ,onset date(during study period, 3years)</time_frame>
    <description>Inflammatory index: High sensitive C-reactive protein (hsCRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Biomarkers(3)</measure>
    <time_frame>enrollment date ,onset date(during study period, 3years)</time_frame>
    <description>Oxidation index:oxidized LDL
The change of biomarkers, t-test will be done by treatment arm(Group A vs B, Group A vs C).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">342</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMGCoA reductase inhibitor continued</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID + Cilostazol 100 mg PO, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMGCoA reductase inhibitor</intervention_name>
    <description>During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.
Dosage regimen: following the package insert of each HMGCoA reductase inhibitor</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMGCoA reductase inhibitor + probucol</intervention_name>
    <description>In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.
Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMGCA reductase inhibitor + probucol + cilostazol</intervention_name>
    <description>In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.
Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Subjects who are at least 20 y of age at the time of informed consent (male or
             female)

          -  2) Subjects with coronary heart disease longer than 3 months.

          -  3) Subjects being treated with HMGCoA reductase inhibitors(Statins)

          -  4) Subjects with an max IMT equal to or greater than 1.2 mm

          -  5) Subjects with an LDL-Cholesterol less than 200mg/dl

          -  6) Subjects whose voluntary written informed consent is obtained for participation in
             this study

        Exclusion Criteria:

          -  1) Subjects who took probucol within 6 months before participation of the study

          -  2) Subjects who took cilostazol within 3 months before participation of the study

          -  3) Subjects with a history of hypersensitivity to probucol or cilostazol

          -  4) Subjects with homozygous familial hyperlipidemia*

          -  5) Subjects with a triglyceride ( TG) level greater than 400mg/dL at screening

          -  6) Subjects with uncontrolled diabetes : HbA1c level greater than 9%

          -  7) Subjects with New York Heart Association (NYHA) classification: Class Ⅲ and Ⅳ

          -  8) Subjects with a QTc interval greater than 450msec(male) 470msec(female)

          -  9) Subjects with serious ventricular arrythmias (frequent episodes of multifocal
             ventricular extrasystole)

          -  10) Subjects with atrial fibrillation (including paroxysmal AF)

          -  11) Subjects with unstable angina

          -  12) Subjects with liver and kidney functions that satisfy the following criteria - AST
             or ALT &gt;100 IU/L, serum creatinine &gt;1.5 mg/dL

          -  13) Subjects who are participating in another clinical trial

          -  14) Subjects with pregnant or possibly pregnant without appropriate contraception
             control. Appropriate contraception control means that Oral contraception for greater
             than 4 weeks, surgical contraception including loop insertion, condom use etc. Women
             who has no possibility of pregnancy because of surgery or menopause should not be
             regarded the subject with possibly pregnant

          -  15) Subjects with clinically significant disorders of blood coagulation

          -  16) Subjects who are not considered by the physicians to be appropriate to participate
             in this trial for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-Hee Oh, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheol Ho Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Hyun Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moo-Hyun Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A medical center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dong-A Medical Center</name>
      <address>
        <city>Seogu</city>
        <state>Busan</state>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-Gu</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boramae Medical Center</name>
      <address>
        <city>Dongjak-Gu</city>
        <state>Seoul</state>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Manzato E. Scandinavian simvastatin study (4S). Lancet. 1994 Dec 24-31;344(8939-8940):1767; author reply 1767-8.</citation>
    <PMID>7997016</PMID>
  </results_reference>
  <results_reference>
    <citation>Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J, Simpson LM, Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation. 1999 Jan 19;99(2):216-23.</citation>
    <PMID>9892586</PMID>
  </results_reference>
  <results_reference>
    <citation>Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998 Nov 5;339(19):1349-57.</citation>
    <PMID>9841303</PMID>
  </results_reference>
  <results_reference>
    <citation>Barnhart JW, Sefranka JA, McIntosh DD. Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol). Am J Clin Nutr. 1970 Sep;23(9):1229-33.</citation>
    <PMID>5450842</PMID>
  </results_reference>
  <results_reference>
    <citation>Tomikawa M, Nakayasu T, Tawara K, Abiko Y. Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice. Atherosclerosis. 1981 Oct;40(2):101-13.</citation>
    <PMID>6946776</PMID>
  </results_reference>
  <results_reference>
    <citation>Tawara K, Tomikawa M, Abiko Y. Mode of action of probucol in reducing serum cholesterol in mice. Jpn J Pharmacol. 1986 Jan;40(1):123-33.</citation>
    <PMID>3959347</PMID>
  </results_reference>
  <results_reference>
    <citation>Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928-31.</citation>
    <PMID>3475709</PMID>
  </results_reference>
  <results_reference>
    <citation>Ishigami M, Yamashita S, Sakai N, Hirano K, Arai T, Maruyama T, Takami S, Koyama M, Kameda-Takemura K, Matsuzawa Y. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest. 1997 Apr;27(4):285-92.</citation>
    <PMID>9134376</PMID>
  </results_reference>
  <results_reference>
    <citation>Rinninger F, Wang N, Ramakrishnan R, Jiang XC, Tall AR. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999 May;19(5):1325-32.</citation>
    <PMID>10323786</PMID>
  </results_reference>
  <results_reference>
    <citation>Matsuzawa Y, Yamashita S, Funahashi T, Yamamoto A, Tarui S. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol. 1988 Jul 25;62(3):66B-72B.</citation>
    <PMID>3394656</PMID>
  </results_reference>
  <results_reference>
    <citation>Daida H, Kuwabara Y, Yokoi H, Nishikawa H, Takatsu F, Nakata Y, Kutsumi Y, Oshima S, Nishiyama S, Ishiwata S, Kato K, Nishimura S, Miyauchi K, Kanoh T, Yamaguchi H. Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]). Am J Cardiol. 2000 Sep 1;86(5):550-2, A9.</citation>
    <PMID>11009277</PMID>
  </results_reference>
  <results_reference>
    <citation>Tardif JC, Cöté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med. 1997 Aug 7;337(6):365-72.</citation>
    <PMID>9241125</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995 Feb 23;332(8):488-93.</citation>
    <PMID>7830729</PMID>
  </results_reference>
  <results_reference>
    <citation>Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol. 2002 Feb 20;39(4):610-6.</citation>
    <PMID>11849859</PMID>
  </results_reference>
  <results_reference>
    <citation>Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb. 2008 Dec;15(6):292-303. Epub 2008 Dec 6. Erratum in: J Atheroscler Thromb. 2009 Mar;16(1):E1.</citation>
    <PMID>19060422</PMID>
  </results_reference>
  <results_reference>
    <citation>Bots ML, Grobbee DE. Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther. 2002 Jul;16(4):341-51. Review.</citation>
    <PMID>12652104</PMID>
  </results_reference>
  <results_reference>
    <citation>Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995 Mar 1;75(7):455-9. Erratum in: Am J Cardiol 1995 Apr 15;75(12):862.</citation>
    <PMID>7863988</PMID>
  </results_reference>
  <results_reference>
    <citation>de Groot E, Jukema JW, Montauban van Swijndregt AD, Zwinderman AH, Ackerstaff RG, van der Steen AF, Bom N, Lie KI, Bruschke AV. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol. 1998 Jun;31(7):1561-7.</citation>
    <PMID>9626835</PMID>
  </results_reference>
  <results_reference>
    <citation>MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation. 1998 May 12;97(18):1784-90. Erratum in: Circulation 1996 Jun 23;97(24):2479.</citation>
    <PMID>9603532</PMID>
  </results_reference>
  <results_reference>
    <citation>Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002 Oct 15;106(16):2055-60.</citation>
    <PMID>12379573</PMID>
  </results_reference>
  <results_reference>
    <citation>Baldassarre D, Franceschini G, Peruzzotti G, Brusoni B, Sirtori CR. Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. J Cardiovasc Pharmacol. 1997 Dec;30(6):784-9.</citation>
    <PMID>9436818</PMID>
  </results_reference>
  <results_reference>
    <citation>Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1942-7.</citation>
    <PMID>9848888</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoshikawa T, Mitani K, Kotosai K, Nozako M, Miyakoda G, Yabuuchi Y. Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. Horm Metab Res. 2008 Jul;40(7):473-8. doi: 10.1055/s-2008-1065348. Epub 2008 Apr 10.</citation>
    <PMID>18404599</PMID>
  </results_reference>
  <results_reference>
    <citation>Park SY, Lee JH, Shin HK, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW. Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells. Korean J Physiol Pharmacol. 2008 Aug;12(4):165-70. doi: 10.4196/kjpp.2008.12.4.165. Epub 2008 Aug 31.</citation>
    <PMID>19967051</PMID>
  </results_reference>
  <results_reference>
    <citation>Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001 Feb 24;357(9256):577-81.</citation>
    <PMID>11558482</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>February 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Byung-Hee Oh</investigator_full_name>
    <investigator_title>Professor of Internal Medicine/Cardiology</investigator_title>
  </responsible_party>
  <keyword>Hyperlipidemias</keyword>
  <keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
  <keyword>Probucol</keyword>
  <keyword>Cilostazol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Probucol</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

